Neurocrine Biosciences (NBIX)

Nasdaq Health Care Biotechnology S&P MidCap 400

$164.63

+4.87 (+3.05%)

Close of Nov 06, 2026 · end-of-day data

Source: Neurocrine Biosciences's 10-K / 10-Q XBRL data on SEC EDGAR · fetched Nov 03, 2026

Revenue, net income & free cash flow

Income statement

fiscal years · USD

Fiscal year	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Revenue	$15.00M	$161.63M	$451.20M	$788.10M	$1.05B	$1.13B	$1.49B	$1.89B	$2.36B	$2.86B
Cost of revenue	$0	$1.25M	$4.89M	—	$10.10M	$14.30M	$23.20M	$39.70M	$34.00M	$52.10M
Gross profit	$15.00M	$160.37M	$446.31M	—	$1.04B	$1.12B	$1.47B	$1.85B	$2.32B	$2.81B
Research & development	$94.29M	$121.83M	$160.52M	—	$275.00M	$328.10M	$463.80M	$565.00M	$731.10M	$1.02B
Selling, general & admin	$68.08M	$169.91M	$248.90M	$354.10M	$433.30M	$583.30M	$752.70M	$887.60M	$1.01B	$1.16B
Operating income	-$147.37M	-$131.36M	$36.80M	$72.30M	$163.00M	$102.50M	$249.00M	$250.90M	$570.50M	$619.10M
Interest expense	$0	$19.52M	$30.50M	$32.00M	$32.80M	$25.80M	$7.10M	$4.60M	—	—
Pre-tax income	-$141.09M	-$142.54M	$21.80M	$46.50M	$106.70M	$101.40M	$213.90M	$332.10M	$486.00M	$705.40M
Income tax	$0	$0	$700.00K	$9.50M	-$300.60M	$11.80M	$59.40M	$82.40M	$144.70M	$226.80M
Net income	-$141.09M	-$142.54M	$21.10M	$37.00M	$407.30M	$89.60M	$154.50M	$249.70M	$341.30M	$478.60M
EBITDA	-$145.92M	-$128.96M	$40.82M	$79.70M	$171.60M	$113.40M	$264.10M	$268.70M	$594.00M	$645.10M
EPS (basic)	$-1.63	$-1.62	$0.23	$0.40	$4.38	$0.95	$1.61	$2.56	$3.40	$4.81
EPS (diluted)	$-1.63	$-1.62	$0.22	$0.39	$4.16	$0.92	$1.56	$2.47	$3.29	$4.67
Diluted shares	86.71M	88.09M	95.40M	95.70M	97.80M	97.90M	98.90M	101.00M	103.70M	102.50M
Gross margin	100.0%	99.2%	98.9%	—	99.0%	98.7%	98.4%	97.9%	98.6%	98.2%
Operating margin	-982.5%	-81.3%	8.2%	9.2%	15.6%	9.0%	16.7%	13.3%	24.2%	21.6%
Net margin	-940.6%	-88.2%	4.7%	4.7%	38.9%	7.9%	10.4%	13.2%	14.5%	16.7%

Balance sheet

fiscal years · USD

Fiscal year	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Cash & equivalents	$83.27M	$254.71M	$141.71M	$112.30M	$187.10M	$340.80M	$262.90M	$251.10M	$233.00M	$713.00M
Short-term investments	—	$261.22M	$509.20M	$558.20M	$613.90M	$370.50M	$726.40M	$780.50M	$843.10M	$767.40M
Receivables	$0	$31.13M	$57.41M	$126.60M	$157.10M	$185.50M	$350.00M	$439.30M	$479.10M	$686.80M
Inventory	$0	$1.02M	$10.86M	$17.30M	$28.00M	$30.50M	$35.10M	$38.30M	$57.40M	$69.00M
Total current assets	$310.44M	$554.92M	$737.78M	$831.00M	$1.02B	$972.80M	$1.45B	$1.61B	$1.72B	$2.52B
Goodwill	—	—	—	—	—	$0	$5.40M	$5.80M	$5.70M	$6.10M
Total assets	$365.09M	$817.59M	$993.15M	$1.31B	$1.73B	$2.07B	$2.37B	$3.25B	$3.72B	$4.63B
Total current liabilities	$30.41M	$54.43M	$88.23M	$565.30M	$186.50M	$245.80M	$537.70M	$654.80M	$507.70M	$743.40M
Total liabilities	$50.21M	$445.45M	$512.39M	$669.10M	$608.50M	$698.50M	$660.90M	$1.02B	$1.13B	$1.38B
Shareholders' equity	$314.88M	$372.20M	$480.80M	$636.90M	$1.13B	$1.37B	$1.71B	$2.23B	$2.59B	$3.25B

Cash flow

fiscal years · USD

Fiscal year	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Operating cash flow	-$106.18M	-$94.33M	$101.40M	$147.00M	$228.50M	$256.50M	$339.40M	$389.90M	$595.40M	$782.70M
Capital expenditures	$4.11M	$6.94M	$24.80M	$14.70M	$10.90M	$23.40M	$16.50M	$28.30M	$38.20M	$34.00M
Free cash flow	-$110.29M	-$101.27M	$76.60M	$132.30M	$217.60M	$233.10M	$322.90M	$361.60M	$557.20M	$748.70M
Investing cash flow	$112.95M	-$251.25M	-$242.90M	-$211.10M	$4.10M	-$130.20M	-$177.10M	-$467.10M	-$126.80M	-$264.40M
Financing cash flow	$2.39M	$516.65M	$29.50M	$32.40M	-$157.80M	$27.40M	-$234.30M	$65.30M	-$486.70M	-$38.30M
Share buybacks	—	—	—	—	—	—	$0	$0	$300.00M	$167.70M
Stock-based compensation	$28.46M	$42.52M	$58.10M	$75.30M	$100.00M	$134.20M	$173.10M	$194.30M	$195.50M	$217.90M
Depreciation & amortization	$1.45M	$2.40M	$4.02M	$7.40M	$8.60M	$10.90M	$15.10M	$17.80M	$23.50M	$26.00M

Income statement

quarters · USD

Quarter ended	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	Sep 2026
Revenue	$515.20M	$515.30M	$590.20M	$622.10M	$627.70M	$572.60M	$687.50M	$794.90M	$805.50M	$814.50M	$959.00M	$1.12B
Cost of revenue	$8.50M	$7.50M	$9.20M	$8.00M	$9.30M	$9.20M	$11.30M	$14.00M	$17.60M	$13.80M	$23.20M	$26.60M
Gross profit	$506.70M	$507.80M	$581.00M	$614.10M	$618.40M	$563.40M	$676.20M	$780.90M	$787.90M	$800.70M	$935.80M	$1.10B
Research & development	$137.50M	$159.40M	$191.10M	$195.00M	$185.60M	$263.20M	$244.30M	$250.00M	$258.20M	$296.20M	$326.70M	$351.80M
Selling, general & admin	$218.90M	$243.10M	$242.00M	$234.30M	$287.80M	$276.50M	$286.30M	$291.60M	$301.80M	$318.50M	$439.70M	$366.30M
Operating income	$150.30M	$99.30M	$145.40M	$183.80M	$142.00M	$23.60M	$145.60M	$239.00M	$210.90M	$193.40M	$151.50M	$331.30M
Interest expense	$1.10M	$1.10M	—	—	—	—	$0	$0	—	—	$2.90M	$300.00K
Pre-tax income	$198.20M	$34.50M	$98.60M	$190.30M	$162.60M	$14.70M	$159.50M	$291.80M	$239.40M	$246.80M	$162.20M	$283.70M
Income tax	$50.50M	-$8.90M	$33.60M	$60.50M	$59.50M	$6.80M	$52.00M	$82.30M	$85.70M	$48.90M	$17.80M	$77.20M
Net income	$147.70M	$43.40M	$65.00M	$129.80M	$103.10M	$7.90M	$107.50M	$209.50M	$153.70M	$197.90M	$144.40M	$206.50M
EBITDA	$155.20M	$104.60M	$151.80M	$189.40M	$148.20M	$30.20M	$151.90M	$245.70M	$217.30M	$200.60M	$159.90M	$340.30M
EPS (basic)	$1.51	$0.43	$0.64	$1.28	$1.03	$0.08	$1.09	$2.11	$1.54	$1.97	$1.43	$2.03
EPS (diluted)	$1.46	$0.42	$0.63	$1.24	$1.00	$0.08	$1.06	$2.04	$1.48	$1.91	$1.39	$1.96
Diluted shares	400.00K	103.60M	103.90M	104.30M	-300.00K	102.50M	101.00M	102.50M	500.00K	103.40M	104.20M	105.20M
Gross margin	98.4%	98.5%	98.4%	98.7%	98.5%	98.4%	98.4%	98.2%	97.8%	98.3%	97.6%	97.6%
Operating margin	29.2%	19.3%	24.6%	29.5%	22.6%	4.1%	21.2%	30.1%	26.2%	23.7%	15.8%	29.5%
Net margin	28.7%	8.4%	11.0%	20.9%	16.4%	1.4%	15.6%	26.4%	19.1%	24.3%	15.1%	18.4%

Balance sheet

quarters · USD

Quarter ended	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	Sep 2026
Cash & equivalents	$251.10M	$396.30M	$139.70M	$349.10M	$233.00M	$194.10M	$264.00M	$340.20M	$713.00M	$266.50M	$332.40M	$641.50M
Short-term investments	$780.50M	$814.30M	$899.20M	$878.90M	$843.10M	$749.40M	$711.60M	$774.60M	$767.40M	$1.05B	$57.40M	$96.40M
Receivables	$439.30M	$450.70M	$468.20M	$481.10M	$479.10M	$516.00M	$595.70M	$728.00M	$686.80M	$768.10M	$887.00M	$957.30M
Inventory	$38.30M	$37.20M	$42.50M	$45.80M	$57.40M	$59.10M	$56.90M	$69.30M	$69.00M	$64.50M	$104.20M	$66.10M
Total current assets	$1.61B	$1.80B	$1.67B	$1.88B	$1.72B	$1.64B	$1.75B	$2.16B	$2.52B	$2.44B	$1.64B	$2.01B
Goodwill	$5.80M	$5.70M	$5.70M	$6.10M	$5.70M	—	—	—	$6.10M	$6.00M	$500.60M	$500.60M
Total assets	$3.25B	$3.47B	$3.31B	$3.54B	$3.72B	$3.69B	$3.89B	$4.27B	$4.63B	$4.91B	$5.36B	$5.63B
Total current liabilities	$654.80M	$712.90M	$398.50M	$429.70M	$507.70M	$522.90M	$546.30M	$638.00M	$743.40M	$831.70M	$874.50M	$984.60M
Total liabilities	$1.02B	$1.09B	$795.80M	$816.10M	$1.13B	$1.15B	$1.20B	$1.26B	$1.38B	$1.50B	$1.67B	$1.75B
Shareholders' equity	$2.23B	$2.39B	$2.51B	$2.72B	$2.59B	$2.54B	$2.69B	$3.00B	$3.25B	$3.41B	$3.69B	$3.88B

Cash flow

quarters · USD

Quarter ended	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	Sep 2026
Operating cash flow	$123.50M	$130.30M	$64.60M	$158.00M	$242.50M	$64.80M	$102.00M	$227.50M	$388.40M	$145.80M	$136.40M	$395.20M
Capital expenditures	$5.40M	$11.20M	$11.60M	$8.10M	$7.30M	$10.70M	$12.50M	$13.20M	-$2.40M	$9.10M	$7.80M	$11.60M
Free cash flow	$118.10M	$119.10M	$53.00M	$149.90M	$235.20M	$54.10M	$89.50M	$214.30M	$386.00M	$136.70M	$128.60M	$383.60M
Investing cash flow	-$201.80M	-$55.00M	-$28.20M	$24.70M	-$68.30M	$14.20M	-$29.00M	-$196.70M	-$52.90M	-$506.20M	-$135.40M	-$11.10M
Financing cash flow	$35.40M	$69.90M	-$293.00M	$26.40M	-$290.00M	-$117.90M	-$3.30M	$45.60M	$37.30M	-$86.10M	$63.40M	-$75.00M
Share buybacks	—	$0	$0	$0	$300.00M	$150.00M	$17.70M	$0	$0	$54.00M	$12.00M	$92.10M
Stock-based compensation	$38.10M	$44.50M	$43.10M	$41.50M	$66.40M	$52.80M	$52.80M	$53.70M	$58.60M	$57.20M	$65.00M	$54.30M
Depreciation & amortization	$4.90M	$5.30M	$6.40M	$5.60M	$6.20M	$6.60M	$6.30M	$6.70M	$6.40M	$7.20M	$8.40M	$9.00M

Quarterly figures are rebuilt from the year-to-date totals companies report — Q4 is the full year minus the first nine months, since no 10-Q is filed for it. Values are as filed; later restatements replace earlier ones. Fiscal years are labelled by the calendar year in which they end.